As a lay person, it seems to me the crux of the GBM Agile results released overnight are that they confirm Kazia's own Phase II trial results that Paxalasib extends overall survival for newly diagnosed gliblastoma patients with unmethylated MGMT promotor status by about 30% or 3 months:
GBM Agile Control (standard treatment) OS 11.89 months, paxalisib OS 15.54 months
Kazia Phase II current standard treatment OS 12.7 months (historical data), Paxalisib 15.7 months
GBM Agile found no significant signal for improved survival under paxalisib in the recurrent disease population.
https://www.msn.com/en-us/health/other/kazia-therapeutics-shares-are-jumping-today-successful-study-for-brain-cancer-treatment/ar-BB1pKZoq
https://www.kaziatherapeutics.com/site/PDF/c48e1a7b-fff2-4115-8c77-1aa8663246e9/KaziareleasesfinaldatafromP2paxalisibtrial
What do people think the drug might be worth for the treatment of GBM Agile patients in the unmethylated MGMT promotor status population, given that we have already conditionally sold the rights to China?
As a lay person, it seems to me the crux of the GBM Agile...
-
- There are more pages in this discussion • 25 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)